Long-Term Follow-up After an Initial Episode of Diverticulitis: What Are the Predictors of Recurrence?

2011 ◽  
Vol 54 (3) ◽  
pp. 283-288 ◽  
Author(s):  
Jason F. Hall ◽  
Patricia L. Roberts ◽  
Rocco Ricciardi ◽  
Thomas Read ◽  
Christopher Scheirey ◽  
...  
Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 366-366 ◽  
Author(s):  
Cassandra C. Deford ◽  
Lauren H. Schwartz ◽  
Jedidiah J. Perdue ◽  
Jessica A. Reese ◽  
Johanna A. Kremer Hovinga ◽  
...  

Abstract Abstract 366 Introduction Recovery from an acute episode of TTP is typically assumed to be complete. However patients from the Oklahoma TTP-HUS Registry have often described persistent problems with memory, concentration, and endurance. Our previous studies have documented long-term deficits in quality-of-life and cognitive functioning. We have also observed an unexpectedly high frequency of severe depression. Therefore we documented the relative frequency of severe depression during long-term follow-up and compared the relative frequency of severe depression in our patients to US and Oklahoma population data. Methods We included all Oklahoma TTP-HUS Registry patients whose initial episode was associated with severe ADAMTS13 deficiency (<10%), 1995–2010, and who were alive in 2004 when our psychiatric evaluations began. Patients completed the Beck Depression Inventory-II (BDI-II) 1–5 times from 2004–2011. The BDI-II is a self-report measure consisting of 21 items. Scores are interpreted as suggesting no/minimal, mild, moderate or severe depression. In 2011, patients who had BDI-II scores indicating moderate or severe depression on at least 1 evaluation had a structured psychiatric interview to support the diagnosis of depression. In 2012, all patients were asked to complete an 8-item measure, the Patient Health Questionnaire-8 (PHQ-8). The relative frequency of patients whose PHQ-8 scores indicated major depression were compared to the relative frequency of major depression determined by the PHQ-8 in the Oklahoma and US populations in the most recent Behavioral Risk Factor Surveillance System (BRFSS) data, 2006 and 2008. Results Of 68 patients who had severe ADAMTS13 deficiency at the time of their initial episode of TTP, 52 were alive in 2004; 47 (90%) were evaluated by the BDI-II. Fifteen (32%) of the 47 patients had scores suggesting severe depression on at least 1 evaluation; 12 were alive in 2011 and 10 (83%) of these 12 patients underwent a structured psychiatric interview; 9 met criteria for a major depressive disorder based on this diagnostic interview. Seven (15%) of the 47 patients had scores indicating only moderate depression; 4 (57%) of these 7 patients underwent a structured psychiatric interview; 1 (25%) met criteria for a major depressive disorder. Thirty-seven (88%) of 42 surviving patients in 2012 were evaluated by the PHQ-8 6.3 years (median) after their initial episode; 7 (18.9%, 95% CI, 8.0–35.2) had scores suggesting major depression, which is significantly greater than the prevalence of major depression in the US (3.4%) and Oklahoma (3.5%). The greater relative frequency of major depression was consistent across demographic subgroups. Conclusion The relative frequency of severe depression is increased in patients during long-term follow-up after recovery from TTP. Recognition and appropriate management of this clinically important health problem are critical components of the care of patients who have survived acute episodes of TTP. Disclosures: Kremer Hovinga: Baxter Healthcare: Consultancy, Research Funding. Terrell:Amgen, Inc.: Consultancy; Baxter, Inc.: Consultancy. George:Alexion, Inc.: Consultancy; Amgen, Inc.: Consultancy, PI for clinical trial involving romiplostim, PI for clinical trial involving romiplostim Other, Research Funding; Baxter, Inc.: Consultancy.


Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 856-856 ◽  
Author(s):  
Deirdra R. Terrell ◽  
Jedidiah J. Perdue ◽  
Johanna Kremer-Hovinga ◽  
Bernhard Lammle ◽  
James N. George ◽  
...  

Abstract Many patients who have recovered from TTP report cognitive abnormalities, often described as difficulty with attention, comprehension, and memory. These abnormalities have never been objectively documented. Also there have been reports of patients with continued abnormal ADAMTS13 activity following complete hematologic recovery; the frequency, duration, and clinical importance of persistent ADAMTS13 deficiency has not been described in a cohort of consecutive patients with long-term follow-up. To evaluate these unresolved issues, we measured neurocognitive function, ADAMTS13 activity, platelet count, and hematocrit (hct) in patients from the Oklahoma TTP-HUS Registry. The Registry has measured ADAMTS13 activity on 172/193 (89%) consecutive patients treated with plasma exchange for their initial episode of clinically diagnosed TTP-HUS from 11/13/1995 to 4/30/2003. 4/30/2003 was selected to assess patients with at least 1 year of follow-up after their initial episode. 29/172 (17%) patients with apparently acquired TTP had ADAMTS13 activity <10% at the onset of their initial episode; 22 patients survived. Although severe ADAMTS13 deficiency characteristic of TTP is usually defined as <5%, our 6 surviving patients with initial ADAMTS13 activity of 5–9% all had ADAMTS13 inhibitors; 2 have relapsed and had ADAMTS13 activity of <5% at the time of their 2nd episode. 21/22 patients, who have had follow-up of 0.25–8.25 years from their most recent episode, were evaluated. 9/21 (43%) patients have had between 1–4 relapses. None of the patients had symptoms or signs of TTP at the time of this assessment. The Rey Auditory-Verbal Learning Test (RAVLT) assesses new learning and recent memory. For new learning 11 (52%) patients and for recent memory 7 (33%) patients were below the 16th percentile for age/gender specific norms (p<0.01 and p=0.03 respectively). The Digit Span (DS) score, which assesses attention and concentration, was below the 25th percentile in 8 (38%) patients (p=0.17). 11/20 (55%) had moderate-severe depression symptoms documented by the Beck Depression Inventory-Second Edition (BDI–II) (8 patients) or by prescribed medication for depression (3 patients). ADAMTS13 activity was abnormal (<50%) in 11/21 patients (52%); 2 patients, who were 4.0 and 8.25 years from their most recent episode, had activity <3% with inhibitors; in the other 9 abnormal patients ADAMTS13 activity was 14–50% (median 35%). 19 patients were not thrombocytopenic (platelet counts 174–659, median 286). 1 patient (ADAMTS13 > 100%) with a platelet count of 105 had developed systemic lupus erythematosus after his initial TTP episode; 1 patient (ADAMTS13=50%) with a platelet count of 134 has had intermittent, mild thrombocytopenia since her initial episode 7 years ago. Five patients had mild anemia (hct 32–40%). Relapses, cognitive function, symptoms of depression, platelet count, and hct were not significantly different between patients with normal or abnormal ADAMTS13 activity. The neurocognitive abnormalities documented here may be related to the initial diffuse thrombotic disease. Depression may contribute to these abnormalities. Persistent abnormal ADAMTS13 activity many years after apparent recovery is common but of uncertain clinical importance since ADAMTS13 levels were not associated with clinical outcomes.


1996 ◽  
Vol 20 (11) ◽  
pp. 666-669 ◽  
Author(s):  
Martin Humphreys ◽  
Alan Ogilvie

Feigned psychosis, although rare, presents considerable diagnostic problems in clinical psychiatric practice. Long-term follow up data are lacking. A retrospective case note study was undertaken of 10 patients described in a previous paper, published in 1970, on the simulation of psychosis. The computerised diagnostic instrument OPCRIT was applied to both index episode and lifetime occurrence of symptoms. All 10 patients were found to have had a major psychotic illness based on lifetime symptoms at 20 year follow-up by DSM–III–R criteria. Eight had met such criteria at the time of the initial episode. Diagnosis in patients thought to be feigning psychotic symptoms changes over time and major mental illness is likely to emerge which may be schizophrenic or affective. The term feigned psychosis should be abandoned and more attention given to why symptoms are accepted as genuine in some cases but not others.


2013 ◽  
Vol 18 (1) ◽  
pp. 164-171 ◽  
Author(s):  
Jussi Nikkola ◽  
Irina Rinta-Kiikka ◽  
Sari Räty ◽  
Johanna Laukkarinen ◽  
Riitta Lappalainen-Lehto ◽  
...  

2019 ◽  
Vol 42 ◽  
Author(s):  
John P. A. Ioannidis

AbstractNeurobiology-based interventions for mental diseases and searches for useful biomarkers of treatment response have largely failed. Clinical trials should assess interventions related to environmental and social stressors, with long-term follow-up; social rather than biological endpoints; personalized outcomes; and suitable cluster, adaptive, and n-of-1 designs. Labor, education, financial, and other social/political decisions should be evaluated for their impacts on mental disease.


2001 ◽  
Vol 120 (5) ◽  
pp. A397-A397
Author(s):  
M SAMERAMMAR ◽  
J CROFFIE ◽  
M PFEFFERKORN ◽  
S GUPTA ◽  
M CORKINS ◽  
...  

2001 ◽  
Vol 120 (5) ◽  
pp. A204-A204
Author(s):  
B GONZALEZCONDE ◽  
J VAZQUEZIGLESIAS ◽  
L LOPEZROSES ◽  
P ALONSOAGUIRRE ◽  
A LANCHO ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document